-
Arsenal's Merino has earned striking role: Arteta
-
Putin offers India 'uninterrupted' oil in summit talks with Modi
-
New Trump strategy vows shift from global role to regional
-
World Athletics ditches long jump take-off zone reform
-
French town offers 1,000-euro birth bonuses to save local clinic
-
After wins abroad, Syria leader must gain trust at home
-
Slot spots 'positive' signs at struggling Liverpool
-
Eyes of football world on 2026 World Cup draw with Trump centre stage
-
South Africa rugby coach Erasmus extends contract until 2031
-
Ex-Manchester Utd star Lingard announces South Korea exit
-
Australia edge ominously within 106 runs of England in second Ashes Test
-
Markets rise ahead of US data, expected Fed rate cut
-
McIlroy survives as Min Woo Lee surges into Australian Open hunt
-
German factory orders rise more than expected
-
India's Modi and Russia's Putin talk defence, trade and Ukraine
-
Flooding kills two as Vietnam hit by dozens of landslides
-
Italy to open Europe's first marine sanctuary for dolphins
-
Hong Kong university suspends student union after calls for fire justice
-
Asian markets rise ahead of US data, expected Fed rate cut
-
Nigerian nightlife finds a new extravagance: cabaret
-
Tanzania tourism suffers after election killings
-
Yo-de-lay-UNESCO? Swiss hope for yodel heritage listing
-
Weatherald fires up as Australia race to 130-1 in second Ashes Test
-
Georgia's street dogs stir affection, fear, national debate
-
Survivors pick up pieces in flood-hit Indonesia as more rain predicted
-
Gibbs runs for three TDs as Lions down Cowboys to boost NFL playoff bid
-
Pandas and ping-pong: Macron ending China visit on lighter note
-
TikTok to comply with 'upsetting' Australian under-16 ban
-
Hope's resistance keeps West Indies alive in New Zealand Test
-
Pentagon endorses Australia submarine pact
-
India rolls out red carpet for Russia's Putin
-
Softbank's Son says super AI could make humans like fish, win Nobel Prize
-
LeBron scoring streak ends as Hachimura, Reaves lift Lakers
-
England all out for 334 in second Ashes Test
-
Hong Kong university axes student union after calls for fire justice
-
'Annoying' Raphinha pulling Barca towards their best
-
Prolific Kane and Undav face off as Bayern head to Stuttgart
-
Napoli's title defence continues with visit of rivals Juventus
-
Nice host Angers with storm clouds gathering over the Riviera
-
OpenAI strikes deal on US$4.6 bn AI centre in Australia
-
Rains hamper Sri Lanka cleanup after deadly floods
-
In India's mining belt, women spark hope with solar lamps
-
After 15 years, Dutch anti-blackface group declares victory
-
Eyes of football world fixed on 2026 World Cup draw with Trump presiding
-
West Indies on the ropes in record run chase against New Zealand
-
'Only a miracle can end this nightmare': Eritreans fear new Ethiopia war
-
Unchecked mining waste taints DR Congo communities
-
McIntosh swims second-fastest 400m free ever in US Open triumph
-
Asian markets mixed ahead of US data, expected Fed rate cut
-
French almond makers revive traditions to counter US dominance
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
D.Schneider--BTB